Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Nov 24, 2020 at 10:43 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via Pfizer announced that the first participant has been dosed in the Phase 3 BASIS study of marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (anti-TFPI) being evaluated for the treatment of people with severe hemophilia A or B, with or without inhibitors.

    article source